Treatments for cancers utilizing cell-targeted therapies and associated research protocols
AssigneeFred Hutchinson Cancer Center
InventorsSoheil Meshinchi, Quy Le, Rhonda Ries, Sommer Castro
Life of this patent
Estimating the term…
Abstract
Targeted therapeutics for the treatment of cancers expressing FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and/or FRAS1 are described. The targeted therapeutics can include a chimeric antigen receptor (CAR) expressed by an immune cell or an antibody-targeted therapeutic. The targeted therapeutics can be used to treat a variety of cancers including solid tumors and blood cancers, such as CBFA2T3-GLIS2 acute myeloid leukemia (C/G AML).
Claims94
A chimeric antigen receptor comprising, when expressed by a cell,
- an extracellular component comprising a binding domain having the sequence as set forth in SEQ ID NO:
- 22 or SEQ ID NO:
- 23;
- an intracellular component comprising an effector domain;
- and
- a transmembrane domain linking the extracellular component to the intracellular component.
A targeted therapeutic molecule comprising a binding domain that binds folate receptor 1 (FOLR1), multiple EGF like domain 10 (MEGF10), heparinase-2 enzyme (HPSE2), killer cell lectin like receptor F2 (KLRF2), protocadherin-19 (PCDH19), or Fraser extracellular matrix complex subunit 1 (FRAS1).
Dependencies are inferred from the claim text.